Active broad-market exchange-traded funds in Friday's regular
SPDR S&P 500 (
iShares MSCI Emerging Markets Index (
iPath S&P 500 VIX ST Futures ETN (
PowerShares QQQ Trust, Series 1 (
iShares Russell 2000 Index (
Monday's Pre-Market Movers
Broad Market Indicators
Broad-market exchange-traded funds, including SPY, IWM and IVV,
were modestly higher in Monday's
. Actively traded PowerShares QQQ (
) was up 0.3%.
U.S. stock futures were also edging higher Monday morning, as
investors sought to regain lost ground from last week's decline,
which included the largest drop in two years for the Standard &
Poor's 500 index. With no economic data scheduled for Monday's
trading session, Wall Street will likely focus on a number of
earnings reports; among the latest, Michael Kors (KORS) slipped
lower after providing weak fiscal Q2 and FY15 guidance despite
better-than-expected fical Q1 results.
Power Play: Consumer
Consumer Staples Select Sector SPDR (XLP), iShares Dow Jones US
Consumer Goods (IYK), and Vanguard Consumer Staples ETF (VDC) were
Retail ETFs SPDR S&P Retail (XRT), PowerShares Dynamic
Retail (PMR), and Market Vectors Retail ETF (RTH) were
Women's clothing producer Michael Kors (KORS) was down 4% after
reporting fiscal Q1 earnings and revenue that topped the Street
view, as its guidance for Q2 and FY 2015 missed expectations. KORS
was down 3.5% at $78.80 in recent pre-market trading Monday.
Winners and Losers
Select Financial Sector SPDRs (XLF) was down flat; Direxion
Daily Financial Bull 3X shares (FAS) was up 1% while its bearish
counterpart, Direxion Daily Financial Bear 3X shares (FAZ) was down
CNA Financial (CNA) reported a slight increase in net operating
income for Q2, ahead of the Street view. Its board also approved
the payment of a quarterly dividend. The insurance company reported
net operating income of $272 million, or $1 per diluted share, up
from a net operating income of $199 million, or $0.74 per diluted
share, a year earlier.
Technology Select Sector SPDR ETF (XLK), iShares Dow Jones US
Technology ETF (IYW), iShares S&P North American Technology ETF
(IGM) and iShares S&P North American Technology-Software Index
(IGV) were inactive. SPDR S&P International Technology Sector
ETF (IPK) was also flat.
Among semiconductor ETFs, SPDR S&P Semiconductor (XSD) and
Semiconductor Sector Index Fund (SOXX) were unchanged.
SuperCom (SPCB) was up 11% after the provider of traditional and
digital identity solutions named a new financial chief and
separately said it was selected as the winning bidder for new
contracts representing more than $22 million in size. The company
named Simona Green as its new CFO, to succeed Doron Ilan. Green
previously served as vice president of finance and operation at
Mercury Scientific & Industrial Products. Under the $22 million
in new contracts, the company said it will provide its various core
and flexible electronic-ID solutions, with potential for additional
follow-on orders in the future as is commonly realized with new
Dow Jones U.S. Energy Fund (IYE) and Energy Select Sector SPDR
(XLE) were both flat.
Seventy Seven Energy (SSE) reported its first quarter of
earnings as a standalone public company. The oilfield-services
company, spun off from Chesapeake Energy on June 30, reported Q2
adjusted net income of $0.17 per diluted share. Analyst estimates
weren't available. Total revenue of $549.46 million was down from
$583.06 million in Q2 2013.
Crude was down 0.25%; natural gas was up 0.9%. United States Oil
Fund (USO) was flat; United States Natural Gas Fund (UNG) was up
Gold was down 0.2%, and silver was up 0.1%. Among rare metal
funds, SPDR Gold Trust (GLD) was up 0.01% and iShares Silver Trust
(SLV) was flat.
Health Care SPDR (XLV) was up 0.3% while health-care funds
iShares Dow Jones US Healthcare (IYH) and Vanguard Health Care ETF
(VHT) were unchanged. Biotech ETF iShares NASDAQ Biotechnology
Index (IBB) was flat.
NanoViricides (NNVC) was up 13% after the nanobiopharmaceutical
company said Monday that it is restarting its program for the
development of a drug that would fight Ebola virus infections,
following the recent Ebola outbreak in West Africa, which has been
declared by the World Health Organization as the deadliest so far.
There are currently no licensed drugs or vaccines for Ebola,
although some vaccines as well as some drug candidates have entered